Buradasınız

Anasayfa » Content

Periton Diyalizinin Uzun Dönem Komplikasyonları

Long-term Complications of Peritoneal Dialysis

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2007
Author NameUniversity of AuthorFaculty of Author
Bookmark/Search this post with
Abstract (Original Language): 
Periton diyalizi 20 yıl önce uygulanmaya başlayan basit, rahat ve ucuz olması nedeni ile kronik böbrek hastalarında yaydın olarak kullanılan bir renal replas-ınan tedavi yöntemidir. Periton diyalizi bu hasta grubunda basan ile uygulanmakla beraber, uzun dönemde bir takım komplikasyonlarla karşılaşılmaktadır. Bu yazıda, periton diyalizinin uzun dönem metabolik ve mekanik komplikasyonları ele alınmaktadır.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_16_pp_62-67.pdf
  • 1
62-67
  • Turkish

REFERENCES

References: 

I Davics S|. Russell L, Bryan J el al, Impact of peritoneal absorption uf glucose tin appetite, protein calabolism ant! survival in ÇAPI) patients, Clin Nephrol 1W6;45 (3): 194-198.
2. DeFronzo RA, lobin JD, Rowe JK ei al. Glucose intolerans in uremia. Quantification of panerealic bela cell sensitivity to glucose and tissue sensitivity to insulin. | Clin Invest 1978;62(2>:42S-43*>.
3 Nurdfors I.. I leimburger O, Lonnqvisl 1 Li al. Pat tissue accumulation during peritoneal dialysis is associated with a polymorphism in uncoupling pit >iein 1. Kidney Int 2O0O;57(4H713-17l9.
i. Diaz-liuxo JA. Peritoneal dialysis prescriptions for diabetic paticnls. Adv Peril Dial. 1999; l>.9l-9S,
% Johnson l)W, E leiv.it; KA, Ptirdie DM el ;il, Is obesity a favo¬rable prognostic factor in peritonea! dialysis patients? Peril Dial Int. 2000;20(6):715~721.
(v O'Riordan V., O'Dtmogliue D|. Kalra PA et al. Changes in lipid profiles in nondiabetic, nonnephrotic patients commencing continuous ambulatory peritoneal dialysis. Adv Ferit Dial. 2000;16:313-316.
". Moberly .IB, Airman RO, Sainuelsson () el al. Alterations in lipoprotein coniposilion in peritoneal dialysis patients. Peril Dial lnt 201I2;22 (21:220-228.
8. National Kidney Foundation. K/DOQ1 clinical practice guidelines for managing dyslipidernias in chronic kidney disease. Am.l Kidney Dis 2003;41:1-91
9. Li PK, Mak TW, Lam CW et al. Lovastatin treatment of dysli-poproteinemia in patients on continuous ambulatory peritoneal dialysis. Peril Dial int 1993;13(2):428-430.
10. Nutescu EA, Shapiro NL: Fzetirnitx:: A selective cholesterol absolution inhibitor. Pharmacotherapy 2003;23 (11):1463-1474.
11. Chcrtow GM, Burke SK. Raggi P; Treat to goal working group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney int 2002;62(l);245-252.
12. Cooper S, Iliescu EA, Morton AR. The relationship between dialysate protein loss and membrane transport status in peritoneal dialysis patients. Adv Perit Dial 2001;17:244-247,
13- Yao Q, Axelsson J, Heimburger O, Stenvinkel P, Lindholm B. Systemic inflammation in dialysis patients with end-stage renal disease: causes and consequences. Minerva Urol Nefrol 2004 Sep;56(3): 237-48.
14. Zalunardo NY, Rose CL, Ma IW, Altmann P. Higher serum C-reaclive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis. Kidney Ini 2007Apr;71(7):687-92.
15. Li FK, Chan LY, Woo JC et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003;42(1):173-183.
IS, Khandelwal M, Oreopoulos DG. Is there a need for low sodium dialysis solution for peritoneal dialysis patients!' Adv Perit Dial 2004;20:156-62.
17. Lameire N. Volume control in peritoneal dialysis patients: role of new dialysis solutions. Blood Purif 2004;22( 1 ):44-54.
18. Saiıa TC, Singh H. Noninfeclious complications of peritoneal dialysis. South Med J 2007 Jan;100(l):54-8.
19- Sweny P. Optimum route of administration of vitamin D in renal failure. Nephrol Dial Transplant 1995;10 Suppl 4:29-32.
20. Weinreich T. Prevention of renal osteodystrophy in peritone¬al dialysis. Kidney Int 1998 Dec;54(6):2226-33.
21. Ponferrada LP, Van Stone JC. Peritoneal dialysis kinetics, Adv Ren Replace Ther 1995 Oct;2(4):341-8.
22. Rashid G, Korzets Z, Bernheim J. Advanced glycation end products stimulate tumor necrosis factor-alpha and interie-ukin-1 beta secretion by peritoneal macrophages in patients on continuous ambulatory periloneal dialysis. Isr Med Assoc J 2006 Jan;8(l);36-9.
23- Macticr RA. The spectrum of peritoneal fibrosing syndromes in peritoneal dialysis. Adv Perit Dial 2000;16:223-8.
24. Miyazaki M, Yuzawa Y. The role of peritoneal fibrosis in encapsulating peritoneal sclerosis. Perit Dial Inl 2005 Apr;25 Suppl 4:S48-56.
25. Kawanishi H, Walanabe H, Moriishi M, Tsuchiya S. Successful surgical management of encapsulating peritoneal sclerosis. Peril Dial Int 2005 Apr;25 Suppl 4:S39-47.
26. Chow KM, Szeto ÇÇ, WongTY et al. Hydrolhorax complicating peritoneal dialysis: Diagnostic value of glucose concentration in pleural fluid aspirate. Perit Dial Int 2002;22:525-528.
27. Tang S, Chui WH, Tang AW et al. Video-assisted thoracoscope talc pleurodesis is effective for maintenance of peritonea! dialysis in acute hydrothorax complicating peritoneal dialysis. Nephrol Dial Transplant 2003;18:804-808.
28. Garda-Urena MA, R

Thank you for copying data from http://www.arastirmax.com